Researchers identify distinct molecular and immune profiles that impact the prognosis of patients with metastatic pancreatic ductal adenocarcinoma.

Read on to learn about new genomic biomarkers that could improve prognosis and treatment strategies for pancreatic ductal ...

Needham analyst Ami Fadia maintained a Buy rating on Immuneering (IMRX – Research Report) today and set a price target of $15.00.Stay Ahead of ...

Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products ...

Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most ... to advance personalized treatment strategies and improve patient ...

We leveraged a cohort of 2,336 PDAC tumors to characterize genomic subtypes and their prognostic correlates across clinical stages. A key finding is that shallow copy gains in KRAS mutant alleles ...

Researchers assessed the association of KRAS mutations in metastatic PDAC with the clinical outcomes and responses to first-line chemotherapy regimens.

“With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA ... the availability of more data or following a more comprehensive review of the data and ...

A total of 43 patients with CLDN18.2-positive advanced PDAC (≥60% tumor cells with membranous staining intensity ≥1+ by IHC) received IBI343 6 mg/kg Q3W monotherapy. All participants had previously ...